'THC And CBD From Marijuana Reduces Agitation In 9 Out Of 10 People With Alzheimer’s Or Other Dementia, Study Shows' - Marijuana Moment
IGC Pharma Inc IGC
$0.25
▼ -0.20%
($0.00)
⬆️ Above Yest. High
⚡ High Volume
🗓️ Earnings Next Week
Open
$0.26
Prev Close
$0.25
Day Range
$0.25 – $0.26
52W Range
$0.24 – $0.50
Market Cap
$24.92M
Beta
0.47
EPS (TTM)
$-0.07
📋 Company Profile
| Industry | Pharmaceuticals |
| Country | US |
| Exchange | NYSE MKT LLC |
| Currency | USD |
| IPO Date | 2006-04-13 |
| Shares Out. | 104,370,000 |
| Website | igcpharma.com/ ↗ |
| Phone | 13015294996 |
| Employees | 70 |
| Revenue | $317,000 |
| Gross Profit | $55,000 |
| Net Income | -$2.4M |
| Free Cash Flow | -$4.8M |
| Total Assets | $9.2M |
| Total Liabilities | $3.1M |
| Equity | $6.1M |
About IGC Pharma Inc
IGC Pharma Inc develops cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer's disease, period cramps, premenstrual syndrome, and chronic pain. The company has investigational drug assets targeting Alzheimer's disease, IGC-AD1, IGC-M3, IGC-1C, and TGR-63, which have demonstrated in Alzheimer's cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer's disease, such as plaques or tangles.
IGC Pharma Inc is a publicly traded company under the ticker symbol IGC on the NYSE MKT LLC, operating in the Pharmaceuticals industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
6 analysts (2026-07-01)